Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Multicenter, Doubled-blind Clinical Trial Comparing the Efficacy and Safety of TAB014 and Lucentis in Neovascular Age-related Macular Degeneration (nAMD) Patients

NCT05461339 is registered in ClinicalTrials.gov with BioDlink Biopharm Co., Ltd. as lead sponsor.

NCT NCT05461339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05461339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Multicenter, Doubled-blind Clinical Trial Comparing the Efficacy and Safety of TAB014 and Lucentis in Neovascular Age-related Macular Degeneration (nAMD) Patients
Lead sponsor
BioDlink Biopharm Co., Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 28, 2022
Completion date
February 28, 2025
Enrollment
488 (estimated)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration